Navigation Links
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Date:4/26/2009

WAYNE, N.J. and EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar(R) (sorafenib) tablets in patients with unresectable stage III or stage IV melanoma was stopped early following a planned interim analysis by the independent Data Monitoring Committee (DMC). The trial was sponsored by the National Cancer Institute (NCI) and led by the Eastern Cooperative Oncology Group (ECOG) under a Clinical Trials Agreement between NCI and Bayer and Onyx. The DMC concluded that the study would not meet the primary endpoint of improved overall survival among patients receiving Nexavar in combination with the chemotherapeutic agents carboplatin and paclitaxel versus patients receiving placebo plus the chemotherapeutic agents. The treatment effect was comparable in each arm. The DMC also reported that there were no unexpected serious side effects, though the final analysis of the data will occur per protocol and statistical analysis plan.

Bayer and Onyx will further review the findings of this analysis to determine what, if any, impact these data might have on other ongoing Nexavar melanoma trials. Data from this study are expected to be presented at an upcoming scientific meeting.

"We're disappointed with the results of the study and that the therapy did not bring benefit to patients with melanoma, a historically difficult tumor to treat," said Todd Yancey, M.D., vice president of clinical development at Onyx. "Onyx and Bayer remain committed to our broad clinical program to investigate the potential of Nexavar in a wide range of cancers, and we intend to build upon the success of Nexavar in our approved indications in hepatocellular carcinoma (liver cancer) and advanced renal cell carcinoma (kidney cancer
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
4. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
7. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
8. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
9. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Yesterday, ... Research,s (Moberg) medical device manufacturing facility. Rep. Kennedy ... advanced neurological monitors facilitate cutting-edge research in neurological ... Kennedy and mental health advocate, Garen Staglin ... dedicated to fostering fundamental changes that will radically ...
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Sept. 21 As consumer healthcare expenses rise, ... customer satisfaction has increased considerably from 2009, according ... National Pharmacy Study(SM) released today. ... http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a ) The study, now in ...
... 21 HealthWarehouse.com, Inc. (OTC Bulletin Board: ... Columbia Medical Associates, an outpatient clinic system offering medical ... partnership to offer patients a 30-day supply of more ... home delivery. Columbia Medical Associate,s "Columbia Care" ...
Cached Medicine Technology:J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 2J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 3J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 4J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies 5HealthWarehouse.com Partners with Columbia Medical Associates to Bring Affordable Healthcare to Washington State 2
(Date:7/13/2014)... 13, 2014 Victorian Hotel has recently ... the rental of bikes for its "Cycle the City" ... Hotel to tour the area using a rental bicycle, ... enthusiasts love to call Vancouver home, as it is ... travel and picturesque journeys through the countryside. Vancouver hotel ...
(Date:7/13/2014)... July 13, 2014 Micro irrigation systems ... proper water dispersal as wells as to maintain soil ... is projected to become a dominant revenue generator for ... methods to reduce resource costs has led to the ... plantations, and has further caused massive demand for micro ...
(Date:7/13/2014)... July 13, 2014 Advanced boilers ... the least amount of fossil fuels, produce high-capacity ... Due to increased global warming and climate change ... to reduce harmful gas emissions and pollutants coming ... market in the global advance boilers market., The ...
(Date:7/13/2014)... According to a new market research ... Component (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), ... - Forecast and Analysis to 2014-2020", published by ... Market is expected to reach $61.70 Billion by ... 2014 to 2020. , Browse 71 market data ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A Massachusetts ... to the cancer risks associated with power morcellators ( ... their story to federal regulators, as they presented poignant ... Food & Drug Administration (FDA) advisory panel meeting convened ... According to the Rochester Democrat and Chronicle, Dr. Hooman ...
Breaking Medicine News(10 mins):Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4
... The contaminant bisphenol-A (BPA)—widely used to make many plastics ... long-term effects in female// development, according to a recent ... ,Lead investigator Hugh S. Taylor, M.D., associate professor ... (Ob/Gyn) at Yale, said the study shows that BPA ...
... (Viramune) is associated with a higher risk of rash, ... of the drug, according to Canadian research published in ... found that individuals who took nevirapine once daily were ... took the drug twice a day. For these reasons, ...
... consumers not to purchase, or use, Wild Kitty Cat Food ... monitoring activities, FDA collected and analyzed a sample of frozen ... product. Cats and other pets consuming this food may become ... if they handle or ingest this cat food, touch pets ...
... government warned on Tuesday of potentially life-threatening twisting of ... is the leading cause of early childhood diarrhea. ... led to the withdrawal of the first rotavirus vaccine ... Administration said it was unknown whether the recently approved ...
... has swung in favor of the coffee//. ,There ... on the relation of coffee with heart diseases. ... and led by Dr. Sarah A. Rosner conducted a research on ... ,This was conducted from 1987 to 1990. Results were ...
... is said to be associated with insecure feeling. This was ... led by Angelo Picardi of Italian National Institute of Health ... was conducted on 61 healthy women who were younger than ... women who were unable to form lasting and permanent relationships ...
Cached Medicine News:Health News:Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose 2Health News:Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose 3Health News:Consumers Warned of Using Cat Food Due to Salmonella Contamination 2Health News:FDA: Rotavirus Vaccine May Harm Infants 2
For the quantitative determination of Creatine Kinase in serum....
For the qualitative determination of magnesium in serum....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: